Fortress Biotech (NASDAQ:FBIO – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Monday, November 16th. Analysts expect Fortress Biotech to announce earnings of ($0.27) per share and revenue of $21.57 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.12. Fortress Biotech had a return on equity of 83.47% and a net margin of 163.32%. The firm had revenue of $18.72 million for the quarter, compared to analyst estimates of $18.30 million.
Fortress Biotech Price Performance
Fortress Biotech stock opened at $1.85 on Monday. The firm has a market cap of $61.70 million, a PE ratio of 0.70 and a beta of 1.27. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.96 and a quick ratio of 3.83. The stock’s fifty day moving average price is $2.21 and its two-hundred day moving average price is $2.76. Fortress Biotech has a one year low of $1.79 and a one year high of $4.53.
Analysts Set New Price Targets
Check Out Our Latest Research Report on FBIO
Fortress Biotech Company Profile
Fortress Biotech, Inc (NASDAQ: FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiary companies and strategic partnerships. Its research and development activities have focused on areas including dermatology, immunology, oncology, rare diseases and other conditions with significant unmet medical needs.
The company’s portfolio has included dermatology products such as ZILXI, a topical minocycline foam for the treatment of inflammatory lesions associated with rosacea, and Qbrexza, a topical treatment for primary axillary hyperhidrosis.
Further Reading
- Five stocks we like better than Fortress Biotech
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
